Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases / 대한소아소화기영양학회지
Pediatric Gastroenterology, Hepatology & Nutrition
;
: 50-56, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-719608
ABSTRACT
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as anti-tumor necrosis factor α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pediatría
/
Calidad de Vida
/
Productos Biológicos
/
Enfermedades Inflamatorias del Intestino
/
Colitis Ulcerosa
/
Enfermedad de Crohn
/
Incidencia
/
Factores de Riesgo
/
Predisposición Genética a la Enfermedad
/
Países en Desarrollo
Tipo de estudio:
Estudio de etiología
/
Estudio de incidencia
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Adulto
/
Humanos
Idioma:
Inglés
Revista:
Pediatric Gastroenterology, Hepatology & Nutrition
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS